Cell Culture Market worth $41.3 billion by 2026 - Global Trends, Share Analysis, Leading Key Players

According to the new market research report "Cell Culture Market by Product (Consumables (Media, Serum, Reagent, Vessels), Equipment (Bioreactor, Centrifuge, Incubator)), Application (Vaccines, mAbs, Diagnostics, Tissue Engineering), End User (Pharma, Biotech, Hospital) - Global Forecast to 2026", published by MarketsandMarkets™, is projected to reach USD 41.3 billion by 2026 from USD 22.8 billion in 2021, at a CAGR of 12.6 % between 2021 and 2026.

OPPORTUNITY: Growing demand for 3D cell culture;

3D cell cultures are gaining demand over 2D cell cultures due to multiple reasons. 2D cell culture methods involve growing cells on flat surfaces as 2D monolayers. However, these cells adhere only to cell culture vessels and attach only to cells at the periphery; this limits multi-dimensional cell cultures. Researchers have come up with 3D cell cultures to resolve these issues. These cultures have proven to be efficient in several studies of basic biological mechanisms, such as cell number monitoring, cell viability, cell proliferation, and cell morphology.

Moreover, 3D cell cultures have greater stability and longer lifespans as compared to 2D cultures. The benefits of 3D cell cultures have attracted several players to invest in this field. In June 2020, Lonza and CELLINK collaborated to offer a 3D bioprinting solution designed to advance complete 3D cell culture workflows. In October 2019, Corning Incorporated added two new 3D culture products, including a 3D cell culture microplate and a matrix for organoid culture, to its cell culture product portfolio. Also, there has been a rise in focus on products like microfluidic organ-on-a-chip models, which are 3D microfluidic cell culture chips engineered to mimic the physiology of an organ. 3D cells are grown in scaffolds within the chambers of a microchip. Various startups in the 3D cell culture space are receiving funding from venture capitalists to accelerate the marketing and distribution of 3D cell culture products. For example, in May 2019, Kiyatec Inc. (US) received USD 3 million in Series 2 funding for developing ex vivo 3D culture technology to model and detect cancer patients' response to drug therapies. In May 2019, TreeFrog Therapeutics (France) raised USD 8.6 million in a Series A funding round for C-Stem, a 3D cell culture system used for mass-producing stem cells with short lead times while preserving genomic integrity.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=559&utm_source=openpr&utm_medium=paidpr

The growth of this market is majorly driven by the growing awareness about the benefits of cell-based vaccines, increasing demand for monoclonal antibodies (mAbs), funding for cell-based research, growing preference for single-use technologies, the launch of advanced cell culture products, and the growing focus on personalized medicine. On the other hand, the high cost of cell biology research is restraining the growth of this market.

The consumables segment accounted for the largest share of the product segment in the cell culture market in 2020.

Based on product, the market is segmented into equipment and consumables. The cell culture equipment market is further segmented into supporting equipment, bioreactors, and storage equipment. The cell culture consumables market is segmented into sera, media & reagents, vessels, and bioreactor accessories. In 2020, the consumables segment accounted for the largest share of the market. The large share and high growth of the consumables segment can be attributed to the repeated purchase of consumables and an increase in funding for cell-based research.

The biopharmaceutical production segment accounted for the largest share of the application segment in the cell culture market in 2020.

Based on application, the market is categorized into biopharmaceutical production, diagnostics, drug discovery & development, tissue engineering & regenerative medicine, and other applications. The biopharmaceutical production segment is further divided into monoclonal antibody production, vaccine production, and other therapeutic protein production. The tissue engineering & regenerative medicine segment is further divided into cell & gene therapy and other tissue engineering & regenerative medicine applications. The biopharmaceutical production segment is estimated to grow at the highest CAGR of 14.1% during the forecast period. The high growth of this segment is attributed to the commercial expansion of major pharmaceutical and biotechnology companies, the increasing demand for mAbs, and the growing regulatory approvals for the production of cell culture-based vaccines.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=559&utm_source=openpr&utm_medium=paidpr

The Asia Pacific region is the fastest-growing region of the cell culture market in 2020.

Based on the region, the global market has been segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The Asia Pacific market is estimated to register the highest CAGR during the forecast period. Government initiatives for research on stem cell therapy, growing geriatric population, the rising prominence of regenerative medicine research, increasing number of researchers in Japan, growth of preclinical/clinical research in China, favorable changes in foreign direct investment (FDI) regulations in the pharmaceutical industry in India, and growth of the pharmaceutical & biopharmaceutical sectors in South Korea are the major factors contributing to the growth of the market in the Asia Pacific.

Key players in the cell culture market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), and Sartorius AG (Germany).

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=559&utm_source=openpr&utm_medium=paidpr

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

This release was published on openPR.